The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway
Open accessAbstract
Genetic deficiency or inhibition of cholesteryl ester transfer protein (CETP) leads to a marked increase in plasma levels of large HDL-2 particles. However, there is concern that such particles may be dysfunctional in terms of their ability to promote cholesterol efflux from macrophages. Recently, the ATP-binding cassette transporter ABCG1, a macrophage liver X receptor (LXR) target, has been shown to stimulate cholesterol efflux to HDL. We have assessed the ability of HDL from subjects with homozygous deficiency of CETP (CETP-D) to promote cholesterol efflux from macrophages and have evaluated the role of ABCG1 and other factors in this process. CETP-D HDL-2 caused a 2- to 3-fold stimulation of net cholesterol efflux compared with control HDL-2 in LXR-activated macrophages, due primarily to an increase in lecithin:cholesterol acyltransferase-mediated (LCAT-mediated) cholesteryl ester formation in media. Genetic knockdown or overexpression of ABCG1 showed that increased cholesterol efflux to CETP-D HDL was ABCG1 dependent. LCAT and apoE contents of CETP-D HDL-2 were markedly increased compared with control HDL-2, and increased cholesterol esterification activity resided within the apoE-HDL fraction. Thus, CETP-D HDL has enhanced ability to promote cholesterol efflux from foam cells in an ABCG1-dependent pathway due to an increased content of LCAT and apoE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The plasma lecithin:cholesterol acyltransferase reaction
Glomset, J. A. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43114-1 · Cited by 2,405
Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor
Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., & Krieger, M. (1996) · Science · doi:10.1126/science.271.5248.518 · Cited by 2,026
Wang, N., Lan, D., Chen, W., Matsuura, F., & Tall, A. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403506101 · Cited by 1,061
Self-citationSterol-dependent Transactivation of theABC1 Promoter by the Liver X Receptor/Retinoid X Receptor
Costet, P., Luo, Y., Wang, N., & Tall, A. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003337200 · Cited by 979
Kennedy, M. A., Barrera, G. C., Nakamura, K., Baldán, Á., Tarr, P., Fishbein, M. C., Frank, J., Francone, O. L., & Edwards, P. A. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.002 · Cited by 883
Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 861
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
Pirillo, A., Norata, G. D., & Catapano, A. L. (2013) · Cardiology · doi:10.1159/000346463 · Cited by 748
Scavenger Receptor BI Promotes High Density Lipoprotein-mediated Cellular Cholesterol Efflux
Ji, Y., Jian, B., Wang, N., Sun, Y., Moya, M. D. L. L., Phillips, M. C., Rothblat, G. H., Swaney, J. B., & Tall, A. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.20982 · Cited by 694
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K., & Shinkai, H. (2000) · Nature · doi:10.1038/35018119 · Cited by 531
Cited by
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport
Rosenson, R. S., Brewer, H. B., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.-C., Phillips, M. C., Rader, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.066589 · Cited by 953
Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942
High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
Pirillo, A., Norata, G. D., & Catapano, A. L. (2013) · Cardiology · doi:10.1159/000346463 · Cited by 748
Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690
Molecular regulation of HDL metabolism and function: implications for novel therapies
Rader, D. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci30163 · Cited by 599
The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis
Rader, D. J., Alexander, E. T., Weibel, G. L., Billheimer, J., & Rothblat, G. H. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800088-jlr200 · Cited by 597
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Yvan-Charvet, L., Ranalletta, M., Wang, N., Han, S., Terasaka, N., Li, R., Welch, C., & Tall, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33372 · Cited by 536
Self-citationMacrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis?
Cuchel, M., & Rader, D. J. (2006) · Circulation · doi:10.1161/circulationaha.104.475715 · Cited by 527
Murphy, A. J., Akhtari, M., Tolani, S., Pagler, T., Bijl, N., Kuo, C.-L., Wang, M., Sanson, M., Abramowicz, S., Welch, C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57559 · Cited by 521
Rosenson, R. S., Brewer, H. B., Chapman, M. J., Fazio, S., Hussain, M. M., Kontush, A., Krauss, R. M., Otvos, J. D., Remaley, A. T., & Schaefer, E. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155333 · Cited by 511
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Tall, A. R. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01898.x · Cited by 436
HDL-targeted therapies: progress, failures and future
Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354
The metabolism and anti-atherogenic properties of HDL
Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., & Barter, P. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800034-jlr200 · Cited by 331
Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall
Getz, G. S., & Reardon, C. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800058-jlr200 · Cited by 319
Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M., Cote, J., Rosko, K., Chavez-Eng, C., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 277
Terasaka, N., Wang, N., Yvan-Charvet, L., & Tall, A. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704602104 · Cited by 274
The Failure of Torcetrapib: Was it the Molecule or the Mechanism?
Tall, A. R., Yvan-Charvet, L., & Wang, N. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000256728.60226.77 · Cited by 267
DUVAL, C., MULLER, M., & KERSTEN, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.003 · Cited by 199
Novel HDL-directed pharmacotherapeutic strategies
deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149
APOE genotype and stress response - a mini review
Dose, J., Huebbe, P., Nebel, A., & Rimbach, G. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0288-2 · Cited by 137
Terasaka, N., Westerterp, M., Koetsveld, J., Fernández-Hernando, C., Yvan-Charvet, L., Wang, N., Sessa, W. C., & Tall, A. R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.213215 · Cited by 107
Self-citationApolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk
Morton, A. M., Koch, M., Mendivil, C. O., Furtado, J. D., Tjønneland, A., Overvad, K., Wang, L., Jensen, M. K., & Sacks, F. M. (2018) · JCI Insight · doi:10.1172/jci.insight.98045 · Cited by 91
Chei, C.-L., Yamagishi, K., Kitamura, A., Kiyama, M., Imano, H., Ohira, T., Cui, R., Tanigawa, T., Sankai, T., Ishikawa, Y., et al. (2013) · Stroke · doi:10.1161/strokeaha.112.674812 · Cited by 58
Naresh Kumar, R., Sundaram, R., Shanthi, P., & Sachdanandam, P. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.016 · Cited by 21
High-Density Lipoprotein Metabolism
Brewer, H. B. (2009) · Clinical Lipidology · doi:10.1016/b978-141605469-6.50008-1 · Cited by 3
Metadata
- Authors
- Matsuura, F.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-05-01
- Volume
- 116
- Issue
- 5
- Pages
- 1435-1442
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2095801584
- Cited by
- 293
- References
- 47
- FWCI
- 32.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.